Rudolph Navari on Olanzapine for Preventing Nausea and Vomiting

Video

Rudolph Navari, professor of Medicine at Indiana University School of Medicine - South Bend, discusses the effectiveness of olanzapine (Zyprexa) in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Rudolph Navari, professor of Medicine at Indiana University School of Medicine South Bend, discusses the effectiveness of olanzapine (Zyprexa) in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy.

In a phase III, randomized, double-blind study, Navari added olanzapine to a standard antiemetic regimen and compared it to a placebo with the same antiemetic regimen.

The standard antiemetic regimen supplemented with olanzapine was significantly effective in preventing nausea and vomiting. This was the first study that used nausea as a primary endpoint.

Olanzapine is currently approved by the FDA as an antipsychotic, but not for the prevention of nausea.

Navari says clinical practice should change to use olanzapine with a standard antiemetic regimen for patients receiving highly emetogenic chemotherapy.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.